Digipath
Home > Boards > US Listed > Biotechs > Intellipharmaceutics International Inc. (IPCI)

MNK Seroquel XR Sales

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
AngeloFoca Member Profile
 
Followed By 11
Posts 1,030
Boards Moderated 0
Alias Born 05/06/14
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/6/2018 11:18:22 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 12/6/2018 11:14:13 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 12/6/2018 6:11:40 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 11/30/2018 5:53:34 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/28/2018 2:44:21 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/28/2018 2:41:17 PM
GD Entertainment and Technology (GDET) Benefit from the transactional side of Bitcoin InvestorsHub NewsWire - 11/28/2018 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/27/2018 5:37:11 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/27/2018 3:38:31 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/27/2018 3:24:23 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/27/2018 3:20:56 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/27/2018 3:17:34 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/27/2018 8:12:16 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/27/2018 6:10:06 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/21/2018 5:25:52 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/21/2018 5:23:41 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/21/2018 4:42:54 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/21/2018 12:05:37 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/21/2018 12:01:51 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/21/2018 6:06:39 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/6/2018 6:10:46 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/6/2018 6:10:14 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/6/2018 6:10:14 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/26/2018 4:30:50 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/26/2018 4:20:44 PM
AngeloFoca   Friday, 11/10/17 04:37:15 PM
Re: AngeloFoca post# 31201
Post # of 38244 
MNK Seroquel XR Sales

$1.7 million 3rd Qtr 2017 Actual
$6.6 million 4th Qtr 2017 Tight Estimate

388% Qtr over Qtr growth... can't assume that kind of growth going forward... but even a 10% growth Qtr over Qtr can be a meaningful thing.

$1.7 million 3rd Qtr 2017 Actual
$6.6 million 4th Qtr 2017 Tight Estimate

********** 10% growth Qtr over Qtr ************

$7.26 million 1st Qtr 2018 Estimate
$7.98 million 2nd Qtr 2018 Estimate
$8.77 million 3rd Qtr 2018 Estimate
$9.64 million 4th Qtr 2018 Estimate

$33.55 million 2018 Sales

$38.56 million 2019 Sales with 0% growth thereafter.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136115642




Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist